CURRENT ISSUES IN THE THERAPY OF HIV-INFECTED PATIENTS WITH GASTROENTERITIS SYNDROME
Main Article Content
Abstract
Gastroenteritis syndrome in HIV-infected patients remains a critical concern worldwide. Gastrointestinal (GI) disorders in this population can be caused by a broad range of opportunistic pathogens, including viruses, bacteria, protozoa, and fungi, often leading to severe, chronic, and life-threatening complications. Despite significant advancements in antiretroviral therapy (ART), morbidity and mortality associated with GI opportunistic infections (OIs) continue to pose substantial challenges, especially in resource-limited settings. Effective diagnosis, treatment, and prevention strategies are paramount for improving the quality of life and clinical outcomes in HIV-infected individuals.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
How to Cite
References
1.Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR Recomm Rep. 2009;58(RR-4):1–207.
2.Muthupandian S, et al. Gastrointestinal opportunistic infections in HIV: Current status and challenges. World J Gastroenterol. 2020;26(31):4619–4633.
3.Stark D, Barratt JL, van Hal S, Marriott D, Harkness J, Ellis JT. Clinical significance of enteric protozoa in the immunosuppressed human population. Clin Microbiol Rev. 2009;22(4):634–650.
4.Cotton MF, Violari A, Otwombe K, et al. Early limited antiretroviral therapy is superior to deferred therapy in HIV-infected infants. Pediatr Infect Dis J. 2020;39(5):413–420.
5.Luma HN, et al. Late presentation to HIV/AIDS care at the Douala General Hospital, Cameroon: Its associated factors, and consequences for HIV/AIDS progression. PLoS One. 2020;15(5):e0233249.
6.Marcotte LM, Chandwani S, Cairns C, Ganesan N, Okafor CN, Freedberg KA. Treatment outcomes in HIV-infected patients with advanced immunosuppression and opportunistic infections: A systematic review. Infect Dis Clin North Am. 2019;33(3):985–997.
7.Nightingale SD, et al. Incidence of Mycobacterium avium-intracellulare complex bacteremia in HIV-infected patients. J Infect Dis. 2019;219(3):437–445.